GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration
Status: | Recruiting |
---|---|
Conditions: | Psychiatric, Pulmonary |
Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
Healthy: | No |
Age Range: | 18 - 50 |
Updated: | 1/11/2018 |
Start Date: | November 2014 |
End Date: | November 2019 |
Contact: | Jessica Costeines, MA |
Email: | jessica.costeines@yale.edu |
Phone: | 203-974-7559 |
The investigators plan to explore the effects of acute pre-treatment with the glucagon like
peptide-1 (GLP-1) agonist, exenatide versus placebo, on the subjective (e.g., euphoric) and
behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment
seeking users of the drug. Additionally, the investigators plan to explore the effects of
sub-chronic (5-day) treatment with exenatide as compared to placebo on the subjective (e.g.,
euphoric) and behavioral (self-administration) effects of cocaine in experienced,
non-treatment seeking users of the drug.
peptide-1 (GLP-1) agonist, exenatide versus placebo, on the subjective (e.g., euphoric) and
behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment
seeking users of the drug. Additionally, the investigators plan to explore the effects of
sub-chronic (5-day) treatment with exenatide as compared to placebo on the subjective (e.g.,
euphoric) and behavioral (self-administration) effects of cocaine in experienced,
non-treatment seeking users of the drug.
Inclusion Criteria:
1. age 18 - 50 years,
2. voluntary, written, informed consent,
3. physically healthy by medical history, physical, neurological, ECG, and laboratory
examinations,
4. DSM-IV criteria for Cocaine Abuse (305.60) or Cocaine Dependence (304.20)
5. recent street cocaine use in excess of amounts to be administered in the current
study,
6. intravenous and/or smoked (crack/ freebase) use,
7. positive urine toxicology screen for cocaine,
8. for females, non-lactating, no longer of child-bearing potential (or agree to practice
effective contraception during the study), and a negative serum pregnancy (β-HCG)
test.
Exclusion Criteria:
1. Other drug dependence (except nicotine) as determined by urine toxicology or interview
2. < 1 year of cocaine dependence,
3. a primary major DSM-IV psychiatric diagnosis (schizophrenia, bipolar disorder, etc.),
unrelated to cocaine,
4. a history of significant medical (cardiovascular) or neurological illness, ie prior
myocardial infarction, current active symptoms of cardiovascular disease / angina,
evidence of cocaine-related cardiovascular symptoms, prior arrhythmias or need for
cardiovascular resuscitation, neurovascular events such as transient ischemic attacks,
stroke, and/or seizures Parameters re: elevations in vital signs are now explicitly
specified under "Safety features built into our one-day self-administration paradigm).
5. current use of psychotropic and/or potentially psychoactive prescription medication,
6. seeking treatment for drug abuse/dependence (for experimental cocaine component),
7. physical or laboratory (β-HCG) evidence of pregnancy.
8. current use of any medication (prescription or over-the-counter) determined to cause
potential drug interactions by the study physicians.
We found this trial at
1
site
New Haven, Connecticut 06508
Principal Investigator: Robert T Malison, MD
Phone: 203-974-7559
Click here to add this to my saved trials